ZAGREB, Nov 30 (Hina) - The first Day of Pliva's Research and Development, during which its representatives informed investors and analysts about the Croatian pharmaceutical company's activities in the fields of development and
presented its research and development strategy, was held in London this week. Pliva management board chairman, Zeljko Covic stressed the company had a long-time tradition in research and development, which is best proved by the one of the most sold drugs to date -- Sumamed. Further confirmation of Pliva's research potentials are three new projects which this years transit from the research phase into the phase of clinical testing. The value of newly developed generic drugs on the markets of Central and eastern Europe in 2005 is estimated at more than US$90 million, Covic said, adding this would secure further investments, which would secure a short-term and lo
ZAGREB, Nov 30 (Hina) - The first Day of Pliva's Research and
Development, during which its representatives informed investors
and analysts about the Croatian pharmaceutical company's
activities in the fields of development and presented its research
and development strategy, was held in London this week.
Pliva management board chairman, Zeljko Covic stressed the company
had a long-time tradition in research and development, which is
best proved by the one of the most sold drugs to date -- Sumamed.
Further confirmation of Pliva's research potentials are three new
projects which this years transit from the research phase into the
phase of clinical testing.
The value of newly developed generic drugs on the markets of Central
and eastern Europe in 2005 is estimated at more than US$90 million,
Covic said, adding this would secure further investments, which
would secure a short-term and long-term growth before the return of
the value of long-term investments.
The profit for licensing Sumamed to Pfizer, Covic said, enabled
further investments, which would most probably increase the value
for stock holders and secure firm foundations for growth even after
the patent ownership in 2005.
Pliva's international research team in Zagreb is cooperating with a
number of companies and global universities and scientific
institutions, besides, Pliva has its own research and development
centres in the Czech Republic, Poland and France.
(hina) lml